Effect of heparin and related glycosaminoglycan on PDGF-induced lung fibroblast proliferation, chemotactic response and matrix metalloproteinases activity

Masahiro Sasaki\textsuperscript{CA}, Masayuki Kashima, Takefumi Ito, Akiko Watanabe, Masaaki Sano, Manabu Kagaya, Takanobu Shioya and Mamoru Miura

Second Department of Internal Medicine, Akita University School of Medicine, 1–1-1 Hondo, Akita 010, Japan

\textsuperscript{CA}Corresponding Author
Tel: +81 18 884 6107
Fax: +81 18 836 2612
E-mail: masahiro@im2.med.akita-u.ac.jp

Fibroblast migration, proliferation, extracellular matrix protein synthesis and degradation are the key events in various biological and pathological processes in pulmonary fibrosis. In addition, biopsy specimens from the lungs of patients with pulmonary fibrosis show increased numbers of mast cells which have metachromatic granules containing heparin, histamine and proteases. Little is known about how these products influence pulmonary fibrosis. In the present study, we investigated the effect of heparin and related glycosaminoglycans on PDGF-induced lung fibroblast proliferation and chemotactic response \textit{in vitro}. In addition, we examined the effect of heparin on both the induction of matrix metalloproteinases (MMPs) and MMPs activity in lung fibroblasts \textit{in vitro}.

Heparin, de-N-sulphated heparin but not heparan sulphate inhibited PDGF-induced lung fibroblast proliferation. In contrast, only heparin inhibited PDGF-stimulated human lung fibroblast chemotaxis. Negatively charged poly-L-glutamic acid had no effect on either fibroblast proliferation or chemotaxis. Thus the negative charge alone cannot account for the anti-proliferative and anti-chemotactic effects of heparin.

Furthermore, heparin and heparan sulphate also had no inhibitory effect on induction of MMPs, including MMP-1 (interstitial collagenase), MMP-2 (gelatinase A) and MMP-9 (gelatinase B). Only heparin inhibited both MMP-1 and MMP-2/MMP-9 activity. Additionally, tissue inhibitor of metalloproteinase type 1 (TIMP-1) and type 2 (TIMP-2) inhibited PDGF-stimulated human lung fibroblast chemotaxis. The ability of heparin to inhibit fibroblast chemotaxis may account for the inhibitory effect of heparin on MMP activity.

The above results suggested that heparin and related glycosaminoglycans differentially regulate PDGF-induced lung fibroblast proliferation, chemotaxis and MMPs activity and further that these effects may have a key role in extracellular matrix remodeling in inflammatory lung disease.

\textbf{Key words:} Heparin, PDGF, Matrix metalloproteinases (MMPs), Lung fibroblasts, Pulmonary fibrosis

\section*{Introduction}

Biopsy specimens from the lungs of patients with pulmonary fibrosis show increased numbers of mast cells\textsuperscript{1–3} which have metachromatic granules containing heparin, histamine and proteases. Morphological studies also suggested fibroblast proliferation, excessive synthesis and deposition of collagen and other extracellular matrix proteins\textsuperscript{4,5} in pulmonary fibrosis. However, less is known about the interaction of fibroblasts, growth factors and extracellular matrix molecules in inflammation.

Platelet-derived growth factor (PDGF), which is one of the most important mitogens derived from various cells including alveolar macrophages and platelets, may implicate the extracellular matrix proteins and matrix metalloproteinases (MMPs)\textsuperscript{6} in wound healing. The role of PDGF in inflammatory lung diseases is consistent with the observation of PDGF-like proteins localised to macrophages and epithelial cells associated with tissue repair of patients with idiopathic pulmonary fibrosis\textsuperscript{7,8}.

Mast-cell mediators may act as growth factors, including histamine and tryptase, to fibroblasts. Hep-
arin, a major component of the mast cell granule matrix and well-known polyanionic anticoagulant, is now recognized as an anti-inflammatory agent. Heparin and heparin-related glycosaminoglycans have numerous other functions, among which are inhibition of fibrin deposition in tissues, inhibition of fibroblast proliferation associated with proteases and inhibition of allergen-induced recruitment of eosinophils into the airway. Heparin and heparan sulphate, which is one of the main extracellular matrix components, also inhibit vascular smooth muscle cell division. This action may indicate that heparin and related glycosaminoglycans play an important role in modulation not only of airway wall remodelling in asthma but also of extracellular matrix remodeling in pulmonary fibrosis.

MMPs are major proteolytic enzymes involved in degrading and remodeling the extracellular matrix. The matrix metalloproteinase-1 (MMP-1) derived from fibroblasts is interstitial collagenase known to degrade collagen types I, II, III and others. The type IV collagenase (MMP-2 and MMP-9), which is now found in fibroblasts and macrophages, has the ability to degrade a wide range of extracellular matrix proteins, including basement membrane collagen type IV, fibronectin and gelatin. Recently, it has been suggested that MMPs including MMP-2, MMP-3 and MMP-9 play a major role in the degradation of the extracellular matrix during tumor cell invasion. In pulmonary fibrosis, MMPs are regulated by numerous factors including growth factors and inflammatory mediators may play a key role in modulating lung tissue injury and extracellular matrix remodeling.

Therefore, in the present study we investigate the possible influence of heparin and glycosaminoglycan on PDGF-induced human lung fibroblast proliferation, chemotaxis and MMPs activity.

**Material and methods**

**Materials**

Recombinant human PDGF-BB was purchased from Genzyme (USA). Heparin (porcine), whose activity was 1000 units per ml, was purchased from Novo Nordisk (Denmark). Heparan sulphate (bovine mucosa), de-N-sulphated heparin and poly-L-gulutamic acid were obtained from Sigma (USA). Anti-hMMP1, anti-hMMP2 and anti-hMMP9 were purchased from Fuji Chemi Co. (Japan), as were recombinant hTIMP-1 and hTIMP-2. Tissue culture plates were obtained from Sumitomo Bakelite (Japan) and transwell culture dishes were from Corning Coster (USA).

**Cell culture, proliferation and adhesion**

Human lung fibroblasts CCL-153 obtained from the American Type Culture Collection (ATCC) were cultured in a cell culture flask, in modified Ham’s F12 (Sigma) supplemented with 10% FCS at 37°C in an atmosphere of 5% CO₂. The cells were plated at 1.0 × 10⁵ cells in a 24-well plate in media with 10% FCS for 72 h then washed three times in F12, and synchronized with serum free F12 for 48 h. Cells were incubated with heparin (0.1–100 μM), heparan sulphate, de-N-sulphated heparin and poly-L-gulutamic acid (0.1–100 g/ml) with serum free media for 24 h. Cells were removed from plates with PBS and EDTA, replaced and suspended in a microtest tube with 1 ml of F12 media. Cell counts and viability were determined by trypan blue exclusion (GIBCO) and counted in a hemocytometer.

**[H³]-Thymidine incorporation assay**

Lung fibroblasts were plated at 1.0 × 10⁵ cells in a 24-well plate in media with 10% FCS until confluence. Cells were washed three times in F12, and incubated in serum-free F12 medium with compounds pulsed with [H³]-thymidine (0.04 μCi/ml). Incorporation of [H³]-thymidine was measured after 24 h by detaching the cells with trypsin solution, harvesting the cells on filters using the Tiltetteck cell harvester and undergoing lysis with distilled water. Radioactivity on the filters was determined by scintillation counting of dpm/well.

**Chemotaxis assay**

Chemotaxis stimulated by PDGF (10 μg/ml) was measured using the modified Boyden chamber as described previously. The test compounds diluted with Ham’s F12 medium were placed lower in wells in the lower chamber. The cells were washed three times in F12, and incubated in serum-free F12 medium with compounds pulsed with [H³]-thymidine (0.04 μCi/ml). Incorporation of [H³]-thymidine was measured after 24 h by detaching the cells with trypsin solution, harvesting the cells on filters using the Tiltetteck cell harvester and undergoing lysis with distilled water. Radioactivity on the filters was determined by scintillation counting of dpm/well.

**Matrix metalloproteinases assay**

An assay to determine matrix metalloproteinases (MMPs) activity was measured by the diffuse fibril method based on that of Gawston and Barrett. This method utilizes FITC labeled type I collagen (human) (MMP-1 activity) or type IV collagen (bovine) (MMP-2/MMP-9 activity) which was affected by collagenases incubated at 37°C or at 42°C to produce soluble fragments that can be separated from intact fibrils by
centrifugation. One unit of MMP-1 or MMP-2/MMP-9 activity is defined as the amount of enzyme degrading 1 μg of collagen per minute at 37 or 42°C. The specificity of the assay was confirmed by identification of MMPs reaction products using an immunofluorescence electrophotometer as described previously.

Reverse transcription polymerase chain reaction amplification (RT-PCR)

Total RNA was extracted from fibroblasts by RNAzol(). First-strand cDNA was prepared from 3 μg total RNA in 30 μL reaction volume, 50 mMTris (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 1 mM dNTPs, 40 U RNAsin inhibitor and 200 U reverse transcriptase.

Oligonucleotide primers for PCR amplification of MMP-1, MMP-2 and MMP-9 were designed according to published sequences for MMP-1, MMP-2 and MMP-9. Primers used were as follows: MMP-1: 5’TGGT-TAGCTTACTGTCAACGCTT, 3’AGAACGAGAACACA- AAGATCTCAGC; MMP-2: 5’CTTTGCAGGAGACAA-GTTCTGG, 3’TGAAGGTGGTGCAGGTATCTGC; and MMP-9: 5’CCATGAGTCCCTGGCAG, 3’TCCCCCTGC- CCCTCAGAGA.

Amplification was performed in a final volume of 25 μL with 10 mMTris (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 1.25 mM dNTPs, 7.5 pmol of each primer and 1.25 of Taq polymerase. After a ‘hotstart’ (95°C, 5 min), each 3 min cycle consisted of 1 min of denaturation at 95°C, annealing at 55°C, and elongation at 72°C. Reactions were run for 30 cycles.

Data analysis

Results are expressed as mean and s.e.mean. A comparison of proliferation and chemotaxis on dose response within experiments was performed by ANOVA. Statistical significance was established at the p<0.05 level. The effects of stimulation/inhibition on fibroblast migration were evaluated using an analysis of variance and were considered statistically significant at the p<0.05 level.

Results

The effect of glycosaminoglycans on PDGF-induced fibroblast proliferation

PDGF induced a concentration related cell proliferation between 0.1 and 100 ng/ml (Fig. 1). Heparin alone (0.1 and 10 U/ml) had no significant effect on fibroblast proliferation. However, at higher concentration heparin (100 U/ml) did cause a significant inhibition of fibroblast proliferation compared with the control (Fig. 1, p<0.05).

Heparin sulphate, de-N-sulphated heparin and poly-L-glutamic acid (0.1–100 μg/ml) had no significant effect on cell proliferation.
PDGF-induced fibroblast proliferation. In the absence of glycosaminoglycan, PDGF-induced proliferation was unaffected by any vehicle as shown by a stimulation index of near unity (Fig. 2). Heparin and de-N-sulphated heparin significantly inhibited PDGF (0.1–100 μg/ml) induced fibroblast proliferation (Fig. 2, p < 0.05). In contrast heparan sulphate and poly-L-glutamic acid had no effect on PDGF-induced fibroblast proliferation (Fig. 2). Cell viability assessed using trypan blue exclusion was found to be greater than 95% in all experiment.

[H³]-thymidine incorporation assay

PDGF induced a concentration-related increase in cell proliferation (142±15% at 1 ng/ml, p < 0.05; 224±18% at 10 ng/ml, p < 0.01) as assessed by [H³]-thymidine incorporation. In agreement with the data obtained when assessing cell proliferation by cell counting, heparin (10 and 100 U/ml) significantly inhibited PDGF-induced proliferation (Table 1, p < 0.05). In contrast, heparan sulphate (100 μg/ml) had a synergistic effect upon PDGF (10 ng/ml)-induced fibroblast proliferation (Table 1), but not significantly.

Effect of heparin and heparan sulphate on chemotaxis

PDGF induced a significant increase in fibroblast chemotaxis (control cell number=4.2±1.2 vs PDGF=15.0±4.2, p < 0.05). Heparin inhibited fibroblast chemotaxis in a concentration-dependent manner (Fig. 3). Chemotaxis (%

Table 1. The effects of heparin and heparan sulphate on the incorporation of [H³]-thymidine by fibroblasts treated with PDGF

|                | Control | PDGF (1 ng/ml) | PDGF (10 ng/ml) |
|----------------|---------|----------------|-----------------|
| **Heparin**    |         |                |                 |
| 0              | 100     | 142 ± 15       | 224 ± 18        |
| 1 U/ml         | 124 ± 8 | 136 ± 7        | 268 ± 18        |
| 10 U/ml        | 67.4 ± 4| 73 ± 10        | 202 ± 13        |
| 100 U/ml       | 38 ± 3  | 55 ± 7         | 81 ± 5          |
| **Heparan sulphate** |     |                |                 |
| 0              | 100     | 142 ± 15       | 224 ± 18        |
| 1 μg/ml        | 114 ± 12| 150 ± 26       | 226 ± 11        |
| 10 μg/ml       | 125 ± 20| 137 ± 32       | 242 ± 18        |
| 100 μg/ml      | 122 ± 17| 147 ± 35       | 244 ± 20        |

Values represent mean ± s.e.mean of the proliferative response above basal levels derived from experiments with six replicates, each mean represents a significant increase (p<0.05) or significant decrease (p<0.05) in the proliferation of fibroblast when compared with control.
of control) was significantly lower at 10 U/ml of heparin than at any other concentration \((p<0.05)\) between 0.1–10 U/ml. In contrast, heparan sulphate (0.1–10 μg/ml) had no significant effect on PDGF-induced fibroblast chemotaxis.

Anti-hMMP1, anti-hMMP2 and anti-hMMP9 had no significant effect on fibroblast chemotaxis, while recombinant hTIMP-1 and hTIMP-2 inhibited fibroblast chemotaxis significantly (Fig. 4).

Matrix metalloproteinases assay

Fibroblasts constitutively express MMP-1 (control levels=3.45±0.52 unit/ml) and MMP-2/MMP-9 (control levels=5.0±0.9 unit/ml) collagen activity. PDGF significantly inhibited fibroblast collagenase activity as assessed by a reduction in MMP-1 but not MMP-2/MMP-9 collagenase activity (Fig. 5, \(p<0.05\)). Heparin but not heparan sulphate inhibited fibroblast MMP-1 and MMP-2/MMP-9 collagenase activity (Fig. 5, \(p<0.05\)).

RT-PCR

PCR using specific oligonucleotide primer sets for MMP-1, MMP-2 and MMP-9 revealed a single amplification product of fibroblast cultured with PDGF. Heparin and heparan sulphate had no inhibitory effect on the induction of MMP-1, MMP-2 and MMP-9 gene expression (data not shown).

Discussion

We demonstrated the ability of PDGF to modulate the induction of MMPs and the activity of MMPs in the present study. Only heparin inhibited fibroblast proliferation, chemotaxis and MMPs activity. Our data suggests that heparin and related glycosaminoglycans differentially regulate PDGF-induced lung fibroblast proliferation, chemotaxis and MMPs activity and may play a key role in extracellular matrix remodeling in inflammatory lung diseases.

Several previous studies suggested that intestinal lung diseases are diffuse inflammatory disorders characterized by an increase in the number of inflammatory cells, fibroblast proliferation, progressive alteration of alveolar-capillary structures and excessive synthesis and deposition of the extracellular matrix protein. These phenomena are induced by various growth factors, cytokines and proteases produced by infiltrating neutrophils, platelets, macrophages, fibroblasts and resident cells. In addition, biopsy specimens from the lungs of patients with pulmonary fibrosis show increased numbers of mast cells that have metachromatic granules acting as growth factors, containing heparin, histamine and proteases. Matrix metalloproteinase also contributes to the role of extracellular matrix turnover and remodeling in pulmonary fibrosis. However, less is known about the interaction of fibroblasts, growth factor and extracellular matrix molecules in inflammation.

PDGF is one of the most important chemoattractants and mitogens associated with tissue repair, a process involving collagen synthesis and remodeling by MMPs. PDGF-like mitogen localized in the macrophages and epithelial cells of patients with idiopathic pulmonary fibrosis has been shown to be an important stimulus for fibroblast proliferation and collagen production. Our present study has demonstrated the ability of PDGF to induce human fibroblast chemotaxis using cell migration assay and to induce proliferation as assessed by cell counting and H\(^3\)-thymidine incorporation methods.
Heparin, a major component of the mast cell granule matrix, is well known as a polyanionic anticoagulant. Heparin related glycosaminoglycans are abundant components of the extracellular matrix molecules and are present on cell surfaces in many tissues. Heparin and related glycosaminoglycans have been reported to inhibit bovine airway smooth muscle division in a concentration-dependent fashion. Similarly, heparin-like glycosaminoglycans have been reported to inhibit the growth of human arterial smooth muscle cells in vitro by binding and inactivating PDGF and also that heparan sulphate regulated the activity of FGF on fibroblast proliferation and migration. These studies illustrate that the anti-proliferative activity of the heparin-like molecule is not limited to airway and vascular smooth muscle but also to human lung fibroblasts.

It is clear that while low concentrations of heparin were ineffective against cell proliferation and DNA synthesis, heparin at high concentrations inhibited cell proliferation and also DNA synthesis in fibroblasts. This effect is unrelated to a loss in cell viability, as assessed by trypan blue exclusion. Furthermore, the inhibitory effect of heparin was unrelated to its anionic charge since other polyanions including poly-L-glutamic acid and heparan sulphate had no effect on cell proliferation. Moreover, sulphation does not appear to be necessary for the inhibitory action of heparin on cell proliferation or DNA synthesis since de-N-sulphated heparin was as effective as heparin in this response. It remains unclear whether the effect of heparin and de-N-sulphated heparin on cell proliferation is related to the chemical inactivation of PDGF. Heparin also inhibited fibroblast migration in the present study, whereas exogenously-administered heparin is known to inhibit cell migration. These findings suggest that endogenously related heparins may inhibit inflammatory cell infiltration by producing an anti-inflammatory effect. Indeed, inflammatory cells are major sources of heparanase which disrupts glycosaminoglycan linkages and results in the release of heparin-like fragments from cellular heparan sulphate.

Persistent inflammation in the airway may thereby influence structural changes including collagen deposition beneath the basement membrane and airway smooth muscle layer thickening as observed in asthma. Recent studies have indicated that matrix metalloproteinases play a role in the degradation of extracellular matrix protein in tumor cell invasion and neutrophil migration. Our present results show that human lung fibroblasts in culture retain MMP-1 and MMP-2/MMP-9 activity. MMP-1—interstitial collagenase in fibroblasts—catalyzes degradation of collagens, type I, II, III and others. MMP-2/MMP-9 has the ability to degrade a wide range of extracellular matrix proteins, including basement membrane collagen type IV, fibronectin and gelatin. Our results demonstrate that PDGF inhibits MMP-1 but not MMP-2/MMP-9 activity in a concentration-dependent fashion and that PDGF differentially regulates MMPs activity, fibroblast proliferation and chemotaxis. We recommend that further studies investigate the effects of PDGF in the regulation of MMPs.

Little is known about the interaction between heparin and MMPs. Our results are significant in the understanding of fibroblast migration to the basement membrane and extracellular matrix and also of the inhibitory effects of heparin on fibroblast migration. We observed that blocking the endogenous MMPs with anti-hMMP1, anti-hMMP2 and anti-hMMP9—which have no effect on the catalytic site of each MMPs—had no effect on fibroblast chemotaxis. In contrast, recombinant hTIMP-1 and hTIMP-2 inhibited fibroblast chemotaxis significantly, which is consistent with the notion that fibroblast migration was thought to be dependent on degradation of collagen. The ability of heparin to inhibit fibroblast chemotaxis may account for the inhibitory effects of heparin on MMPs activity. This hypothesis is further supported by our result that heparin had no inhibitory effect on induction of MMP-1 and MMP-2/MMP-9 mRNA. Further experiments are required to understand the mechanism by which heparin inhibits MMPs activity.

In conclusion, our results provide clear evidence that heparin inhibits PDGF-induced human lung fibroblast proliferation, chemotaxis and MMPs activity. Thus, endogenously-released heparin-like molecules may play an important role in extracellular matrix turnover and remodelling in inflammatory lung diseases.

ACKNOWLEDGMENTS: This work was supported in part by a Grant-in-Aid for Scientific Research C (07670653) from the Ministry of Education, Science and Culture, Japan.

References

1. Kawanami O, Ferrans VJ, Fulmer JD, Crystal RG. Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders Lab Invest 1979; 40:717–34.
2. Fortoul TI, Barrios R. Mast cells and idiopathic lung fibrosis. Arch Intern Med 1990; 215:3–10.
3. HeardB, DewartA, OrrinB. Apposition of fibroblasts to mast cells and lymphocytes in normal human lung and in cryptogenic fibrosing alveolitis. Ultrastructure and cell perimeter measurements. J Pathol 1992; 166:303–10.
4. SelmanM, MontanoM, RampsC, ChapelR. Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. Thorax 1986; 41:355–9.
5. RaughGL. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis 1985; 131:281–9.
6. RossR, RaineSB, Bowen-PopeDE. The biology of platelet derived growth factor. Crit Rev Biochem Mol Biol 1986; 46:155–69.
7. Marinetti V, RomWN, GrotendorstGR, MartinGR, CrystalRG. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med 1987; 317:202–9.
8. Butler DM, Leizer T, Hamilton JA. Stimulation of human synovial fibroblast and synthesis by platelet-derived growth factor and fibroblast growth factor. J Immunol 1989; 142:3098–103.
9. Colvin RB, Johnson RA, Mihm MC, Dvorak HF. Role of the clotting system in cell-mediated hypersensitivity. Fibrin deposition in delayed skin reaction in man. J Exp Med 1973; 138:686–98.
Effect of heparin and related glycosaminoglycan

10. Schwartz LB, Bradford TR. Regulation of tryptase from human lung mast cells by heparin stabilization of the active tetramer. *Biol Chem* 1986;261:7372–9.

11. Sayama S, Itozo RV, Lazarus GS, Schechter NM. Human skin chymotryptsin-like protease chymase. Subcellular location to mast cell granules and interaction with heparin and other glycosaminoglycans. *J Biol Chem* 1987;262:8008–15.

12. Lider O, Mekori YA, Miller T, Bar-Tana R, Vlodavsky I, Bahrav E, Cohen I R, Nuparsek Y. Inhibition of T lymphocyte degranulation by heparin prewet T cell migration and T-cell-mediated immunity. *Eur J Immunol* 1990;20:495–9.

13. Seeds EA, Hanss J, Page CP. The effect of heparin and related proteoglycans on allergen and PAF-induced eosinophil infiltration. *J Lipid Mediators* 1993;7:269–78.

14. Sasaki M, Herd CM, Page CP. Effect of heparin and a low-molecular weight heparanoid on PAI-induced airway responses in neonatally immunized rabbits. *Br J Pharmacol* 1993;110:107–12.

15. Fager G, Hansson GK. Human arterial smooth muscle cells in culture. Effects of platelet-derived growth factor and heparin on growth in vitro. *Exp Cell Res* 1988;176:319–35.

16. Kilfather SA, Tagose S, Perez AC, Okona-Mensa K, Martin R, Page CP. Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. *Br J Pharmacol* 1995;114:1442–6.

17. Karnovsky MJ, Edelman ER. Heparin/heparan sulphate regulation of vascular smooth muscle cell behavior. In: Blac J, Page CP, eds. *Airways and Vascular Remodelling in Asthma and Cardiovascular disease implication for Therapeutic Intervention*. London: Academic Press, 1994.

18. Bowler SD, Smith SM, Lavercombe PS. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. *J Clin Sci* 1985;42:3154–8.

19. Emelianov AA, Mekori YA, Vlodavsky I, Bahrav E, Cohen I, Nuparsek Y. Inhibition of T lymphocyte degranulation by heparin prewet T cell migration and T-cell-mediated immunity. *Eur J Immunol* 1990;20:495–9.

20. Butler DM, Lessier T, Hamilton JA. Stimulation of human synovial fibroblast and synthesis by platelet-derived growth factor and fibroblast growth factor. *J Immunol* 1989;142:3098–103.

21. Unemori EN, Bhasani N, Wang M, Lee S, McGuire J, Amento EP. Interleukin-1 and transforming growth factor-β synergistic stimulation of metalloproteinases, PGE2, and proliferation in human fibroblasts. *Exp Cell Res* 1994;210:166–71.

22. Yahalom J, Eldor A, Fuchs Z, Vlodavsky I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparatinase, *J Clin Invest* 1984;74:1842–9.

23. Lundgren R, Soderberg M, Horsefield R, Stening R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhalated steroid. *Eur Respir* 1988;1:885–9.

24. Seppa H, Grotendorst G, Seppa S, Schiffmann E, Martin GR. Platelet-derived growth factor is chemotactic for fibroblasts. *J Cell Biol* 1982;92:584–8.

25. Antoniades HD, Font MA, Avila RE, Galanosopoulos T, Neville-Golden J, Maxwell M, Selman M. Platelet-derived growth factor in idiopathic pulmonary fibrosis. *J Clin Invest* 1990;86:1055–64.

26. Martinez Y, Rom WN, Grotendorst GR, Martin GR, Crystal RG. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. *N Engl J Med* 1987;317:202–9.

27. Butler DM, Lessier T, Hamilton JA. Stimulation of human synovial fibroblast and synthesis by platelet-derived growth factor and fibroblast growth factor. *J Immunol* 1989;142:3098–103.

28. Unemori EN, Bhasani N, Wang M, Lee S, McGuire J, Amento EP. Interleukin-1 and transforming growth factor-β synergistic stimulation of metalloproteinases, PGE2, and proliferation in human fibroblasts. *Exp Cell Res* 1994;210:166–71.

29. Yahalom J, Eldor A, Fuchs Z, Vlodavsky I. Degradation of sulfated proteoglycans in the subendothelial extracellular matrix by human platelet heparatinase. *J Clin Invest* 1984;74:1842–9.

30. Lundgren R, Soderberg M, Horsefield R, Stening R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhalated steroid. *Eur Respir* 1988;1:885–9.

31. Ebina M, Yaegasi H, Chiba R, Takahashi T, Motomiya M, Tanemura M. Hyperreactive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles: A morphometric study. *Am Rev Respir Dis* 1990;141:327–32.

32. Roche WR, Beasley CE, Williams JH, Holgate ST. Subepithelial fibrosis in the bronch of asthmatic patients revealed by thickening of bronchial muscles: A morphometric study. *Am Rev Respir Dis* 1990;141:327–32.

33. Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell-derived collagenase stimulatory factor increase expression of interstitial collagenase, and 72/44 gelatinase. *Cancer Res* 1993;53:3154–8.

34. Ip A, Nakajima S, Sawaguri Y, Negao H, Mori Y. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. *Br J Cancer Res* 1995;71:1039–45.

35. Declaus C, Delcourt C, d’Ortho M, Boyer V, Lafumin C, Harf A. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. *Am J Respir Cell Mol Biol* 1996;14:288–95.

**Accepted 2 May 2000**